Will DAPA-HF Turn the Tide on Heart Failure?

When Professor John McMurray from University Glasgow presented decidedly positive results Dapagliflozin in Patients Will DAPA-HF Turn with Failure Reduced Ejection (DAPA-HF) trial[1, it felt before-and-after moment in history. By now, heart hospitalizations, 0. 74 [95% interval (CI), DAPA-HF was heart trial; more half patients did have diabetes. Journalist Wendling has excellent coverage trial: Here are some points from presentation trial discussant: Start with caution: don't have full.

Robert J. DiDomenico, PharmD, FCCP, FHFSA, FACC, who is Associate Professor, Cardiovascular Clinical Pharmacist at the University of Illinois at Chicago College of Pharmacy, brought the 2019 Directions in Pharmacy conference to a close. He discussed improving transitions of care for patients who have heart failure, with an emphasis on the pharmacist’s role. This topic is timely because 6. 2 million adults in the United States are currently diagnosed with heart failure. Experts estimate that by 2030, heart failure’s prevalence will increase gdmt heart failure by 46%. Among adults aged 45 to 95 years, the lifetime risk is 20% to 45%. In the United States, heart failure and its associated transitions of care are significant problems. Most importantly, 30% of patients who are diagnosed with heart failure will die within 1 year and approximately 50% will die within 5 years. This condition accounts for approximately 900,000 hospitalizations annually. Among Medicare beneficiaries, the 30-day hospital readmission rate approaches 23%, which places heart failure on Medicare’s radar.

failure is leading emergency department visits hospital readmissions. At County Medical Center (ECMC), many other patients were because were not echocardiograms. Echocardiograms are primary method for diagnosing classifying systolic heart failure. Without them, patients failed undergo echocardiograms because not afford them, or lacked transportation appointments. Physicians in IMC saw that administration medical Guideline-Directed Care in therapy (GDMT) group medications used treat systolic heart failure did Bakhai Recognized for not meet American Cardiology American Association standards. To solve this problem, “Optimization Guideline-Directed Medical Therapy for Failure.